Rapport Therapeutics, Inc. (RAPP) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Rapport Therapeutics, Inc. (RAPP): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 38/100 — a percentile rank of Rapport Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $1.6B |
| P / S | 80.6× |
| EV / EBITDA | -10.2× |
| Gross margin | 100.0% |
| Operating margin | -767.6% |
| Net margin | -685.8% |
| Return on equity | -32.4% |
| ROIC | -42.7% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Independent of the events above — derived from Rapport Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact